Charles la Porte1. 1. Ottawa Health Research Institute, University of Ottawa, Ottawa Hospital Division of Infectious Diseases, Ottawa, Ontario K1H 8L6, Canada. claporte@ohri.ca
Abstract
PURPOSE OF REVIEW: This review discusses the use of the inhibitory quotient in light of therapeutic drug monitoring of antiretroviral drugs. The inhibitory quotient is a parameter that combines viral resistance data with drug exposure data, and has its main role in therapeutic drug monitoring of protease inhibitors in experienced patients. Data from recent clinical studies investigating inhibitory quotient cutoffs to be used in therapeutic drug monitoring will be reviewed. In addition points for discussion regarding the use and study of inhibitory quotients will be presented. RECENT FINDINGS: A number of studies generated data on the use of the inhibitory quotient in general and the genotypic inhibitory quotient in particular. Most of these studies define a cutoff inhibitory quotient value, above which the virological response rate is higher. These cutoff values can be used in therapeutic drug monitoring and give guidance to the clinician on dose adjustments. Genotypic inhibitory quotient cutoff values are available for amprenavir, atazanavir, darunavir, lopinavir, saquinavir and tipranavir. SUMMARY: The inhibitory quotient is becoming a valuable tool in therapeutic drug monitoring. At this moment most data are available for the genotypic inhibitory quotient. Nevertheless, a consensus needs to be reached on a number of items, including the methods to study inhibitory quotient as well as the mathematical and virological background.
PURPOSE OF REVIEW: This review discusses the use of the inhibitory quotient in light of therapeutic drug monitoring of antiretroviral drugs. The inhibitory quotient is a parameter that combines viral resistance data with drug exposure data, and has its main role in therapeutic drug monitoring of protease inhibitors in experienced patients. Data from recent clinical studies investigating inhibitory quotient cutoffs to be used in therapeutic drug monitoring will be reviewed. In addition points for discussion regarding the use and study of inhibitory quotients will be presented. RECENT FINDINGS: A number of studies generated data on the use of the inhibitory quotient in general and the genotypic inhibitory quotient in particular. Most of these studies define a cutoff inhibitory quotient value, above which the virological response rate is higher. These cutoff values can be used in therapeutic drug monitoring and give guidance to the clinician on dose adjustments. Genotypic inhibitory quotient cutoff values are available for amprenavir, atazanavir, darunavir, lopinavir, saquinavir and tipranavir. SUMMARY: The inhibitory quotient is becoming a valuable tool in therapeutic drug monitoring. At this moment most data are available for the genotypic inhibitory quotient. Nevertheless, a consensus needs to be reached on a number of items, including the methods to study inhibitory quotient as well as the mathematical and virological background.
Authors: Micaela B Reddy; Peter N Morcos; Sophie Le Pogam; Ying Ou; Karl Frank; Thierry Lave; Patrick Smith Journal: Antimicrob Agents Chemother Date: 2012-04-02 Impact factor: 5.191
Authors: Meizhen Feng; Nancy A Sachs; Min Xu; Jay Grobler; Wade Blair; Daria J Hazuda; Michael D Miller; Ming-Tain Lai Journal: Antimicrob Agents Chemother Date: 2016-03-25 Impact factor: 5.191
Authors: Craig R Rayner; Patrick F Smith; David Andes; Kayla Andrews; Hartmut Derendorf; Lena E Friberg; Debra Hanna; Alex Lepak; Edward Mills; Thomas M Polasek; Jason A Roberts; Virna Schuck; Mark J Shelton; David Wesche; Karen Rowland-Yeo Journal: Clin Pharmacol Ther Date: 2021-03-09 Impact factor: 6.875
Authors: Marta Boffito; Laura Waters; Pedro Cahn; Roger Paredes; Justin Koteff; Jean Van Wyk; Tia Vincent; James Demarest; Kimberly Adkison; Romina Quercia Journal: AIDS Res Hum Retroviruses Date: 2019-10-21 Impact factor: 2.205